News
06-03-2013, 06:10 AM
NewLink Genetics Corporation, an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from two clinical studies with indoximod, an orally administered small molecule drug candidate that inhibits the IDO pathway.
More... (http://www.news-medical.net/news/20130603/NewLink-Genetics-announces-results-from-two-clinical-studies-with-indoximod.aspx)
More... (http://www.news-medical.net/news/20130603/NewLink-Genetics-announces-results-from-two-clinical-studies-with-indoximod.aspx)